DPP4 and infection: These antibodies inhibit RBD from binding the host receptor dipeptidyl peptidase 4 (hDPP4; also known as CD26) [4], An alternative strategy is to use virus-specific therapeutic human antibodies that can be rapidly developed to neutralize the virus during infection.